---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-045605"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T13:37:31.800488+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience closes $100M PIPE; stockholders approve divestiture of FYARRO business

## Summary
- Gross proceeds of $100M from PIPE led by Ally Bridge Group; 21.6M shares at $2.40 and 20.1M pre-funded warrants at $2.3999.
- Stockholders approved sale of FYARRO business to KAKEN INVESTMENTS INC. (16.6M for, 3.5M against).
- Equity plan amended to increase shares from 2.0M to 8.3M; annual reserve increase to 5% of outstanding.
- Proceeds from PIPE and FYARRO sale, plus existing cash, expected to fund operations into 2028.
- PIPE use includes upfront payments to WuXi Biologics and general corporate purposes.

## SEC filing metadata
- accession: 0001193125-25-045605
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312525045605/0001193125-25-045605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312525045605/d892218d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-045605
- JSON: https://secwatch.observer/filing/0001193125-25-045605.json
- Plain text: https://secwatch.observer/filing/0001193125-25-045605.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.